These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10716499)

  • 21. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.
    Lucia MB; Golotta C; Rutella S; Rastrelli E; Savarino A; Cauda R
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):635-7. PubMed ID: 16044020
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiviral treatment of HIV infection.
    Thomas MG; Ellis-Pegler RB
    N Z Med J; 1998 Sep; 111(1074):353-4. PubMed ID: 11039818
    [No Abstract]   [Full Text] [Related]  

  • 23. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome.
    Wanke CA
    AIDS; 1999 Jul; 13(11):1287-93. PubMed ID: 10449280
    [No Abstract]   [Full Text] [Related]  

  • 24. Higher antiviral activity of antiretroviral regimens including protease inhibitors.
    de Mendoza C; Soriano V; Rodríguez-Rosado R; González-Lahoz J
    AIDS; 1999 May; 13(8):998-9. PubMed ID: 10371186
    [No Abstract]   [Full Text] [Related]  

  • 25. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
    Perloff MD; von Moltke LL; Fahey JM; Daily JP; Greenblatt DJ
    AIDS; 2000 Jun; 14(9):1287-9. PubMed ID: 10894301
    [No Abstract]   [Full Text] [Related]  

  • 26. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins.
    Gimenez F; Fernandez C; Mabondzo A
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):649-58. PubMed ID: 15167283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Human immunodeficiency virus and antiretroviral therapy resistance].
    Quirós E; Torti C; Carosi G
    Enferm Infecc Microbiol Clin; 2000 May; 18(5):234-7. PubMed ID: 10974768
    [No Abstract]   [Full Text] [Related]  

  • 28. [New trends in HIV].
    Volkert R
    Dtsch Med Wochenschr; 1998 Sep; 123(38):A7. PubMed ID: 9787287
    [No Abstract]   [Full Text] [Related]  

  • 29. From the Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
    JAMA; 1996 Nov; 276(19):1546. PubMed ID: 8918842
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
    Berginc K; Trdan T; Trontelj J; Kristl A
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.
    Soriano V; de Mendoza C
    HIV Clin Trials; 2002; 3(3):249-57. PubMed ID: 12032884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 33. Protease inhibitors: the current status.
    Dauer B
    J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
    [No Abstract]   [Full Text] [Related]  

  • 34. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
    Kim JY; Park YJ; Lee BM; Yoon S
    Anticancer Res; 2019 Jul; 39(7):3757-3765. PubMed ID: 31262902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tribulations and trials in HIV disease, Part 2.
    Boyle BA
    AIDS Read; 2006 Jun; 16(6):291-4. PubMed ID: 16795918
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
    Hicks C
    AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.
    Haraguchi S; Ho SK; Morrow M; Goodenow MM; Sleasman JW
    J Leukoc Biol; 2011 Oct; 90(4):653-60. PubMed ID: 21504949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 39. HIV-protease inhibitors.
    Flexner C
    N Engl J Med; 1998 Apr; 338(18):1281-92. PubMed ID: 9562584
    [No Abstract]   [Full Text] [Related]  

  • 40. The daunting challenge of keeping HIV suppressed.
    Cohen J
    Science; 1997 Jul; 277(5322):32-3. PubMed ID: 9229768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.